AWcorna (ARCoV) / Academy of Military Medical Sciences, Suzhou Abogen Biosci, Walvax - LARVOL DELTA

Rational development of a combined mRNA vaccine against COVID-19 and influenza. (PubMed, NPJ Vaccines) - "Then, ARIAV was combined with our COVID-19 mRNA vaccine ARCoV, which encodes the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, to formulate the final combined vaccine, AR-CoV/IAV. More importantly, AR-CoV/IAV immunization protected mice from coinfection with IAV and the SARS-CoV-2 Alpha and Delta variants. Our results highlight the potential of the LNP-mRNA vaccine platform in preventing COVID-19 and influenza, as well as other respiratory diseases."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. (PubMed, Cell Res) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. (PubMed, iScience) - "Structure analysis of one representative antibody identified a novel epitope with a high degree of conservation among different variants. Collectively, these results demonstrate that the RBD trimer mRNA vaccine serves as a promising vaccine candidate against SARS-CoV-2 variants and beyond."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. (PubMed, Lancet Microbe) - "The acceptable safety profile, together with the induction of strong humoral and cellular immune responses, support further clinical testing of ARCoV at a large scale. National Key Research and Development Project of China, Academy of Medical Sciences China, National Natural Science Foundation China, and Chinese Academy of Medical Sciences."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2

Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. (PubMed, Signal Transduct Target Ther) - "Finally, extensive stability assays showed that ARCoV can be stored at 2-8 °C for at least 6 months without decrease of immunogenicity. All these promising results strongly support the ongoing clinical trial."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above (clinicaltrials.gov) - P3; N=28000; Recruiting; Sponsor: Walvax Biotechnology Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase III Clinical Study to Evaluate the Protective Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate in Population Aged 18 Years and Above (clinicaltrials.gov) - P3; N=28000; Not yet recruiting; Sponsor: Walvax Biotechnology Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases